Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 13.42%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of ...

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their weight loss when they stop taking Wegovy.

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms, Lexicon ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.